© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Roflumilast Cream 0.15% Approved for Treatment of Atopic Dermatitis in People Aged 6 Years and Older
July 11, 2024
The steroid-free cream was developed for long-term use and has been proven safe in an open-label extension study following successful phase 3 trials.
FDA Issues CRL to Novo Nordisk for Once-Weekly Insulin Icodec
July 11, 2024
The agency is concerned about manufacturing processes involved in production and about the proposed indication for adults with type 1 diabetes.
In the Old and Very Old, Statins Appear Safe for Primary CVD Prevention, New Analysis Finds
July 10, 2024
Continuous statin use among adults aged 75 years and older resulted in a mean relative risk reduction in CVD of 28% without heightened safety concerns, a new study found.
Prenatal RSV Vaccine Not Associated with Preterm Birth, According to First Real-World Data
July 09, 2024
Data from a study performed during the first season the shot was available expand on clinical trial evidence and support the safety of RSVpreF, authors wrote.
Weight Loss with Tirzepatide Significantly Greater than with Semaglutide: New Data
July 08, 2024
Tirzepatide-treated participants were 3 times more likely than those treated with semaglutide to reach weight loss of 15% or greater, the head-to-head study found.
Exercise Plus GLP-1 RA May Preserve BMD During Weight Loss, Study Finds
July 03, 2024
The preserved bone mass observed in participants taking liraglutide and exercising was seen despite weight reduction levels similar to outcomes with semaglutide and tirzepatide.
Lilly's Donanemab Approved by FDA for Treatment of Early Symptomatic AD
July 02, 2024
Donanemab, now 1 of 2 antiamyloid medications available, is unique based on evidence that it can be used in limited duration treatment, based on removal of plaque.
First Consensus Guidance Published on Monitoring Early-Stage Type 1 Diabetes
July 02, 2024
The international statement targets primary care clinicians and endocrinologists with detailed guidance on monitoring disease progression and providing education.
UPDATE: ACIP Vote Unanimous to Recommend Merck 21-Valent Pneumococcal Shot for Older Adults
July 01, 2024
The novel vaccination is recommended as an option for adults aged 65 years and older who have not received a pneumococcal conjugate vaccine.
FDA Accepts 2 NDAs, Grants Priority Review for Crinecerfont for Pediatric, Adult CAH
July 01, 2024
Neurocrine Biosciences made the announcement and said, if approved in December, crinecerfont will be the first new treatment and treatment approach to CAH in 70 years.